• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Meibomian Gland Dysfunction Market

    ID: MRFR/HC/26085-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Meibomian Gland Dysfunction Market Research Report By Dysfunction Type (Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction), By Disease Severity (Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction), By Treatment Type (Medication, Surgery, Lifestyle Modifications), By Distribution Channel (Hospitals and Clinics, Pharmacies, Online Retailers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East an...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Meibomian Gland Dysfunction Market Research Report — Global Forecast till 2034 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Infographic

    Meibomian Gland Dysfunction Market Summary

    The Global Meibomian Gland Dysfunction Market is projected to grow from 5.68 USD Billion in 2024 to 10.3 USD Billion by 2035, reflecting a robust CAGR of 5.59%.

    Key Market Trends & Highlights

    Meibomian Gland Dysfunction Key Trends and Highlights

    • The market valuation is expected to reach 10.3 USD Billion by 2035, indicating substantial growth opportunities.
    • From 2025 to 2035, the market is anticipated to expand at a CAGR of 5.59%, highlighting a steady increase in demand.
    • In 2024, the market is valued at 5.68 USD Billion, laying a strong foundation for future growth.
    • Growing adoption of innovative treatment options due to increasing awareness of Meibomian Gland Dysfunction is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.68 (USD Billion)
    2035 Market Size 10.3 (USD Billion)
    CAGR (2025-2035) 5.59%

    Major Players

    Johnson & Johnson Vision, Novartis, Roche Holdings, Pfizer, Shimer, Allergan, Sun Pharmaceutical Industries, Valeant Pharmaceuticals, Santen Pharmaceutical, TearLab, Merck, Regeneron, BVI Medical, EyeGate Pharmaceuticals, Bausch + Lomb

    Meibomian Gland Dysfunction Market Trends

    The Meibomian Gland Dysfunction (MGD) market is characterized by the rising prevalence of dry eye disease, technological advancements in diagnostic and treatment modalities, and increasing awareness about eye health.

    Key market drivers include the growing geriatric population, increased screen time, and environmental factors. Opportunities for exploration lie in the development of innovative treatments, such as punctual plugs, cyclosporine A, and Intense Pulsed Light therapy.

    Recent trends include the adoption of telemedicine for remote patient monitoring and the integration of artificial intelligence in diagnostic and treatment planning.

    The market is expected to witness steady growth in the coming years, driven by the increasing demand for effective MGD treatments and the rising prevalence of ocular surface diseases.

    The increasing prevalence of Meibomian Gland Dysfunction among various demographics suggests a growing need for effective treatment options and innovative therapeutic approaches.

    National Eye Institute

    Meibomian Gland Dysfunction Market Drivers

    Increasing Prevalence of Dry Eye Disease

    The rising incidence of dry eye disease, a primary contributor to Meibomian Gland Dysfunction, is a notable driver of the Global Meibomian Gland Dysfunction Market Industry. Factors such as aging populations and increased screen time are exacerbating this condition. In 2024, the market is projected to reach 5.68 USD Billion, reflecting the growing demand for effective treatments. As awareness of dry eye symptoms increases, more patients seek medical attention, thereby expanding the market. This trend is expected to continue, with the market anticipated to grow at a CAGR of 5.59% from 2025 to 2035, potentially reaching 10.3 USD Billion by 2035.

    Market Segment Insights

    Meibomian Gland Dysfunction Market Dysfunction Type Insights

    This can lead to a number of symptoms, including dry eye, irritation, and inflammation. Evaporative MGD is caused by a deficiency in the production of meibum, which is the oily substance that coats the surface of the eye and helps to keep it moist.

    This can also lead to dry eyes and other symptoms. Mixed MGD is a combination of both obstructive and evaporative MGD.

    The obstructive MGD segment accounted for the largest share of the market in 2023 and is projected to continue to grow at a steady pace over the forecast period.

    This is due to the increasing prevalence of dry eye disease, which is a major risk factor for obstructive MGD.

    The evaporative MGD segment is also expected to experience significant growth over the forecast period, due to the rising demand for treatments for dry eye disease.

    Meibomian Gland Dysfunction Market Disease Severity Insights

    The Meibomian Gland Dysfunction Market segmentation by disease severity can be categorized into mild, moderate, and severe.

    The market for mild Meibomian Gland Dysfunction held the largest share in 2023, accounting for approximately 55% of the total market revenue. This is due to the high prevalence of mild symptoms, such as dry eyes, irritation, and inflammation.

    The moderate segment is expected to grow at a CAGR of 5.8% from 2025 to 2034, reaching a market size of USD 9.79 billion by 2034. This growth is attributed to the increasing awareness of the condition and the availability of effective treatments.

    The severe segment held the smallest market share in 2023, but it is projected to grow at the highest CAGR of 6.2% over the forecast period. This is due to the rising prevalence of severe dry eye disease and the development of new therapies.

    Meibomian Gland Dysfunction Market Treatment Type Insights

    The Meibomian Gland Dysfunction Market is segmented by Treatment Type into Medication, Surgery, and Lifestyle Modifications. Medication is the largest segment, accounting for over half of the market share.

    The market growth for Medication is driven by the increasing prevalence of Meibomian Gland Dysfunction and the availability of effective medications to treat the condition.

    Surgery is a less common treatment option, but it is sometimes necessary to remove severely blocked Meibomian glands.

    Lifestyle Modifications, such as warm compresses and eyelid massage, can help to improve symptoms of Meibomian Gland Dysfunction and prevent the condition from worsening.

    The market growth is attributed to the increasing prevalence of the condition, the rising demand for effective treatments, and the growing awareness of Meibomian Gland Dysfunction among healthcare professionals and the general population.

    Meibomian Gland Dysfunction Market Distribution Channel Insights

    The distribution channel segment plays a crucial role in the Meibomian Gland Dysfunction Market. Hospitals and clinics are expected to dominate the market with a significant share due to the presence of specialized ophthalmologists and advanced diagnostic and treatment facilities.

    Pharmacies are also anticipated to hold a substantial market share, driven by increasing awareness and convenience for patients. Online retailers are gaining traction, offering a wider selection of products and doorstep delivery, contributing to the growth of the market.

    The Meibomian Gland Dysfunction Market reached USD 5.09 billion in 2023 and is expected to grow at a CAGR of 5.58% to reach USD 8.3 billion by 2032.

    Get more detailed insights about Meibomian Gland Dysfunction Market Research Report — Global Forecast till 2034

    Request Free Sample

    Regional Insights

    The Meibomian Gland Dysfunction Market is segmented regionally into North America, Europe, APAC, South America, and MEA.

    North America is expected to dominate the market in 2023 with a market revenue of USD 2.2 billion, owing to the high prevalence of dry eye disease and the presence of major market players in the region.

    Europe is expected to follow North America with a market revenue of USD 1.8 billion in 2023, driven by the increasing awareness of MGD and the availability of advanced treatment options.

    APAC is projected to witness the fastest growth during the forecast period, with a CAGR of 6.5% from 2025 to 2034.

    This growth can be attributed to the rising disposable income, increasing healthcare expenditure, and growing awareness about eye care in the region.

    South America and MEA are expected to account for a smaller share of the Meibomian Gland Dysfunction Market revenue in 2023 but are anticipated to grow at a steady pace during the forecast period.

    Meibomian Gland Dysfunction Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    Major players in the Meibomian Gland Dysfunction Market are constantly trying to outdo each other in terms of innovation and product offerings.

    Leading Meibomian Gland Dysfunction Market players are focusing on developing new and improved treatments for MGD, as well as expanding their product portfolios to include a wider range of products.

    The Meibomian Gland Dysfunction Market is also seeing a growing number of mergers and acquisitions as companies look to consolidate their position in the market and gain access to new technologies and markets.

    The Meibomian Gland Dysfunction Market Competitive Landscape is expected to remain highly competitive in the coming years as new players enter the market and existing players continue to innovate and expand their product offerings.

    One of the leading companies in the Meibomian Gland Dysfunction Market is Johnson & Johnson Vision. The company offers a wide range of products for the treatment of MGD, including prescription medications, over-the-counter treatments, and devices.

    Johnson & Johnson Vision is also a leader in research and development and is constantly working to develop new and improved treatments for MGD.

    Another major player in the Meibomian Gland Dysfunction Market is Novartis. The company offers a range of products for the treatment of MGD, including prescription medications and over-the-counter treatments.

    Novartis is also a leader in research and development and is constantly working to develop new and improved treatments for MGD.

    Key Companies in the Meibomian Gland Dysfunction Market market include

    Industry Developments

    The market growth is attributed to the increasing prevalence of dry eye disease, rising awareness about MGD, and technological advancements in diagnostic and treatment modalities.

    Key market players are investing in research and development to introduce innovative products and expand their market presence.

    Recent developments include the launch of TearCare's LipiFlow Thermal Pulsation System for the treatment of MGD and the FDA approval of Novaliq's CyclASol sterile ophthalmic solution for the management of evaporative dry eye disease.

    These advancements are expected to drive market growth in the coming years.

    Future Outlook

    Meibomian Gland Dysfunction Market Future Outlook

    The Meibomian Gland Dysfunction Market is projected to grow at a 5.59% CAGR from 2024 to 2035, driven by increasing awareness, technological advancements, and rising prevalence of dry eye conditions.

    New opportunities lie in:

    • Develop innovative drug delivery systems for targeted treatment of Meibomian Gland Dysfunction.
    • Invest in telemedicine platforms to enhance patient access to specialized care.
    • Create educational programs to raise awareness about Meibomian Gland Dysfunction among healthcare professionals.

    By 2035, the Meibomian Gland Dysfunction Market is expected to achieve substantial growth, reflecting evolving patient needs and treatment advancements.

    Market Segmentation

    Meibomian Gland Dysfunction Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Meibomian Gland Dysfunction Market Treatment Type Outlook

    • Medication
    • Surgery
    • Lifestyle Modifications

    Meibomian Gland Dysfunction Market Disease Severity Outlook

    • Mild Meibomian Gland Dysfunction
    • Moderate Meibomian Gland Dysfunction
    • Severe Meibomian Gland Dysfunction

    Meibomian Gland Dysfunction Market Dysfunction Type Outlook

    • Obstructive Meibomian Gland Dysfunction
    • Evaporative Meibomian Gland Dysfunction
    • Mixed Meibomian Gland Dysfunction

    Meibomian Gland Dysfunction Market Distribution Channel Outlook

    • Hospitals and Clinics
    • Pharmacies
    • Online Retailers

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    5.68 (USD Billion)
    Market Size 2025    6.00 (USD Billion)
    Market Size 2034    9.79 (USD Billion)
    Compound Annual Growth Rate (CAGR)    5.58 % (2025 - 2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled Roche Holdings, Johnson Johnson Vision, Pfizer, Shimer, Allergan, Sun Pharmaceutical Industries, Valeant Pharmaceuticals, Santen Pharmaceutical, TearLab, Merck, Regeneron, BVI Medical, EyeGate Pharmaceuticals, Novartis, Bausch + Lomb
    Segments Covered Dysfunction Type, Disease Severity, Treatment Type, Distribution Channel, Regional
    Key Market Opportunities Increasing prevalence of dry eye disease Rising adoption of advanced diagnostic and treatment technologies Growing awareness of MGD Technological advancements in MGD treatments Expanding healthcare infrastructure in emerging markets
    Key Market Dynamics Technological advancements, rising prevalence of dry eye diseases, increasing awareness, untapped emerging markets, and growing investment in research and development
    Countries Covered North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What was the market size of the Global Meibomian Gland Dysfunction Market in 2024?

    The Global Meibomian Gland Dysfunction Market was valued at approximately USD 5.58 billion in 2024.

    What is the anticipated CAGR of the Global Meibomian Gland Dysfunction Market from 2025 to 2034?

    The Global Meibomian Gland Dysfunction Market is projected to grow at a CAGR of approximately 5.58% from 2025 to 2034.

    Which region is expected to hold the largest market share in the Global Meibomian Gland Dysfunction Market?

    North America is expected to account for the largest market share in the Global Meibomian Gland Dysfunction Market throughout the forecast period.

    What are the key factors driving the growth of the Global Meibomian Gland Dysfunction Market?

    The rising prevalence of dry eye disease, increasing awareness about MGD, and advancements in treatment options are the primary factors driving the growth of the Global Meibomian Gland Dysfunction Market.

    Who are some of the major players operating in the Global Meibomian Gland Dysfunction Market?

    Some of the major players operating in the Global Meibomian Gland Dysfunction Market include Bausch + Lomb, Allergan, Novartis, Johnson Johnson, and TearScience.

    What are the different types of MGD treatments available in the market?

    Common MGD treatments include warm compresses, eyelid massage, artificial tears, prescription medications, and surgical interventions.

    How is the Global Meibomian Gland Dysfunction Market segmented?

    The Global Meibomian Gland Dysfunction Market is segmented based on treatment type, end-user, and region.

    What is the impact of MGD on the overall eye health?

    MGD can lead to chronic dry eye, corneal scarring, and vision impairment if left untreated.

    Is there a cure for MGD?

    While there is no definitive cure for MGD, treatments can help manage the symptoms and prevent further complications.

    What are the emerging trends in the Global Meibomian Gland Dysfunction Market?

    Advancements in diagnostic techniques and the development of novel treatment modalities are emerging trends in the Global Meibomian Gland Dysfunction Market.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027